Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -124.83% is 17045% below its 5-year average of -0.73%, near the low end of its 5-year range (-124.83%–6.95%).
As of the fiscal period ended Tuesday, June 30, 2026. 101.75% below its 12-month average of -61.87%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -124.83%.
RETURN ON EQUITY (ROE)
-124.83%
RETURN ON EQUITY (ROE) AVG TTM
-61.87%
RETURN ON EQUITY (ROE) AVG 3Y
-4.45%
RETURN ON EQUITY (ROE) AVG 5Y
-0.73%
RETURN ON EQUITY (ROE) AVG 10Y
0.85%
RETURN ON EQUITY (ROE) AVG 15Y
-3.36%
RETURN ON EQUITY (ROE) AVG 20Y
-33.06%
CURRENT VS TTM AVG
-101.75%
CURRENT VS 3Y AVG
-2702.20%
CURRENT VS 5Y AVG
-17044.64%
CURRENT VS 10Y AVG
-14715.39%
CURRENT VS 15Y AVG
-3614.06%
CURRENT VS 20Y AVG
-277.54%
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-197.14%
vs the sector median at left
Vanda Pharmaceuticals Inc.
Market Cap
$271.81M
Return on Equity (ROE)
-124.83%
TTM Avg
-61.87%
3Y Avg
-4.45%
5Y Avg
-0.73%
Market Cap
$270.80M
Return on Equity (ROE)
-4.68%
TTM Avg
-68.17%
3Y Avg
-57.88%
5Y Avg
-49.64%
Market Cap
$266.92M
Return on Equity (ROE)
-82.12%
TTM Avg
-62.12%
3Y Avg
-56.53%
5Y Avg
-50.41%
Market Cap
$266.59M
Return on Equity (ROE)
-5.95%
TTM Avg
-61.29%
3Y Avg
-64.14%
5Y Avg
-41.58%
Market Cap
$265.78M
Return on Equity (ROE)
-184.27%
TTM Avg
-57.34%
3Y Avg
-61.84%
5Y Avg
-87.31%
Market Cap
$264.25M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$280.37M
Return on Equity (ROE)
-56.36%
TTM Avg
-35.98%
3Y Avg
25430.43%
5Y Avg
20391.58%
Market Cap
$262.92M
Return on Equity (ROE)
-430.72%
TTM Avg
122.09%
3Y Avg
211.60%
5Y Avg
136.09%
Market Cap
$281.54M
Return on Equity (ROE)
-27.36%
TTM Avg
-12.73%
3Y Avg
-30.52%
5Y Avg
-39.12%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. (VNDA) | $271.81M | -124.83% | -61.87% | -4.45% | -0.73% |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $270.80M | -4.68% | -68.17% | -57.88% | -49.64% |
| Fate Therapeutics, Inc. (FATE)vs › | $266.92M | -82.12% | -62.12% | -56.53% | -50.41% |
| SAB Biotherapeutics, Inc. (SABS)vs › | $266.59M | -5.95% | -61.29% | -64.14% | -41.58% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $265.78M | -184.27% | -57.34% | -61.84% | -87.31% |
| Scribe Therapeutics Inc. (SCTX)vs › | $264.25M | N/A | N/A | N/A | N/A |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $280.37M | -56.36% | -35.98% | 25430.43% | 20391.58% |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $262.92M | -430.72% | 122.09% | 211.60% | 136.09% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.54M | -27.36% | -12.73% | -30.52% | -39.12% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | -39.55% | -28.46% | -79.02% | -63.95% |
ROE
-124.8%
ROA
-66.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -124.83% |
| 2026-03-31 | -85.32% |
| 2025-12-31 | -67.38% |
| 2025-09-30 | -18.07% |
| 2025-06-30 | -13.76% |
| 2025-03-31 | -8.65% |
| 2024-12-31 | -3.51% |
| 2024-09-30 | -3.03% |
| 2024-06-30 | -2.01% |
| 2024-03-31 | -0.90% |
| 2023-12-31 | 0.46% |
| 2023-09-30 | 2.17% |
| 2023-06-30 | 2.76% |
| 2023-03-31 | 2.98% |
| 2022-12-31 | 1.19% |
| 2022-09-30 | 1.26% |
| 2022-06-30 | 2.16% |
| 2022-03-31 | 3.60% |
| 2021-12-31 | 6.57% |
| 2021-09-30 | 6.95% |
| 2021-06-30 | 6.74% |
| 2021-03-31 | 6.74% |
| 2020-12-31 | 5.15% |
| 2020-09-30 | 4.39% |
| 2020-06-30 | 26.38% |
| 2020-03-31 | 28.02% |
| 2019-12-31 | 28.12% |
| 2019-09-30 | 30.36% |
| 2019-06-30 | 9.59% |
| 2019-03-31 | 7.73% |
| 2018-12-31 | 9.15% |
| 2018-09-30 | 4.98% |
| 2018-06-30 | 0.51% |
| 2018-03-31 | -2.01% |
| 2017-12-31 | -11.85% |
| 2017-09-30 | -10.99% |
| 2017-06-30 | -7.77% |
| 2017-03-31 | -10.38% |
| 2016-12-31 | -13.71% |
| 2016-09-30 | -24.93% |
| 2016-06-30 | -33.91% |
| 2016-03-31 | -34.15% |
| 2015-12-31 | -29.97% |
| 2015-09-30 | 30.60% |
| 2015-06-30 | 35.18% |
| 2015-03-31 | 23.94% |
| 2014-12-31 | 12.55% |
| 2014-03-31 | -203.09% |
| 2013-12-31 | -45.90% |
| 2013-09-30 | -38.00% |
| 2013-06-30 | -376.98% |
| 2013-03-31 | -368.38% |
| 2012-12-31 | -279.29% |
| 2012-09-30 | -174.69% |
| 2012-06-30 | -122.32% |
| 2012-03-31 | -66.49% |
| 2011-12-31 | -29.28% |
| 2011-09-30 | -5.52% |
| 2011-06-30 | 10.57% |
| 2011-03-31 | 17.18% |
| 2010-12-31 | 19.06% |
| 2010-09-30 | -12.42% |
| 2010-06-30 | -50.43% |
| 2010-03-31 | -108.24% |
| 2009-12-31 | -155.70% |
| 2009-09-30 | -116.03% |
| 2009-06-30 | -111.90% |
| 2009-03-31 | -91.70% |
| 2008-12-31 | -110.96% |
| 2008-09-30 | -122.27% |
| 2008-06-30 | -125.46% |
| 2008-03-31 | -111.80% |
| 2007-12-31 | -88.46% |
| 2007-09-30 | -65.68% |
| 2007-06-30 | -47.74% |
| 2007-03-31 | -47.93% |
| 2006-12-31 | -237.36% |
| 2006-09-30 | -158.22% |
| 2006-06-30 | -109.41% |
| 2006-03-31 | -256.99% |
| 2005-12-31 | -77.89% |
